Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Blood (2024) 143 (13): 1231–1241.

https://doi.org/10.1182/blood.2023022204

Published: 2024

Includes: Supplemental data

Journal Articles

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Blood (2022) 140 (Supplement 1): 412–414.

https://doi.org/10.1182/blood-2022-160244

Published: 2022

Journal Articles

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Blood (2022) 140 (1): 16–24.

https://doi.org/10.1182/blood.2022015728

Published: 2022

Journal Articles

Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL

Blood (2022) 139 (17): 2706–2711.

https://doi.org/10.1182/blood.2021014648

Published: 2022

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Blood (2021) 138 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2021-153421

Published: 2021

Journal Articles

Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Sairah Ahmed, Ian W. Flinn, Matthew Mei, Peter A. Riedell, Philippe Armand, Natalie S Grover, Andreas Engert, Natalia Lapteva, Paul I. Nadler, Aung Myo, Helen E. Heslop

Blood (2021) 138 (Supplement 1): 3847.

https://doi.org/10.1182/blood-2021-146100

Published: 2021

Journal Articles

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

David H. Quach, PhD, Haran R. Ganesh, BS, Sachin Thakkar, PhD, Luis Becerra-Dominguez, BS, Birju Mehta, MS, Silvana Perconti, MS, Eric Anderson, BS, Emily M. Hsieh, MD, Olga Dakhova, MD, Huimin Zhang, BS, Bambi J. Grilley, RPh, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD DSc, Carlos A. Ramos, MD, Rayne H. Rouce, MD, Natalia Lapteva, PhD, Cliona M. Rooney, PhD

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-141491

Published: 2020

Journal Articles

Rapidly-Generated EBV-Specific T Cells (EBVST-cells) to Treat Type 2 Latency Lymphoma

Rayne H. Rouce, MD, Birju Mehta, Sandhya Sharma, Serena Kimi Perna, MD, Benjamin Shin, Vicky Torrano, Fnu Spoorthi, Natalia Lapteva, PhD, Catherine M. Bollard, MD, Adrian P. Gee, PhD, Carlos A. Ramos, MD, Shannon Inman, Karen L. Hodgkin, Kurt C. Gunter, MD, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD, Cliona M. Rooney, PhD

Blood (2016) 128 (22): 2990.

https://doi.org/10.1182/blood.V128.22.2990.2990

Published: 2016

Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Michael Boyiadzis, MD MHSc, Mounzer Agha, MD, Robert L Redner, MD, Alison Sehgal, MD, Annie Im, MD, Jing-Zhou Hou, Rafic Farah, MD, Kathleen A. Dorritie, MD, Anastasios Raptis, MD PhD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Hans Klingemann, MD PhD, Hong Wang, PhD, Natalia Lapteva, PhD, Mei Zhuyong, MD, Lisa H Butterfield, PhD, Cliona M. Rooney, PhD, Theresa L Whiteside, PhD

Blood (2016) 128 (22): 1649.

https://doi.org/10.1182/blood.V128.22.1649.1649

Published: 2016

Journal Articles

Optimizing the Manufacture of CAR-T Cells for Clinical Applications

Pradip Bajgain, Roopa Mucharla, Usanarat Anurathapan, Natalia Lapteva, Ann M. Leen, PhD, Helen E. Heslop, MD, Cliona M. Rooney, PhD, Juan F. Vera, MD

Blood (2012) 120 (21): 348.

https://doi.org/10.1182/blood.V120.21.348.348

Published: 2012

Journal Articles

Optimal Xenogeneic Adoptive Transfer of Human NK Cells: Fresh NK Cells and IL-15 Administration Are Superior to Frozen NK Cells and IL-2

Jakub Tolar, MD, PhD, Julie Curtsinger, PhD, Ron McElmurry, Valarie McCullar, Michael R. Verneris, MD, Frits van Rhee, MD, PhD, Natalia Lapteva, Cliona M Rooney, PhD, John E. Wagner, MD, Bruce R. Blazar, MD, Jeffrey S. Miller, MD

Blood (2012) 120 (21): 346.

https://doi.org/10.1182/blood.V120.21.346.346

Published: 2012

Journal Articles

Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order

Susann Szmania, Natalia Lapteva, PhD, Tarun K. Garg, PhD, Joshuah D Lingo, Amy D Greenway, Amberly Bost, Katie Stone, Junaid Khan, Emily Woods, Bijay Nair, MD, Dario Campana, MD, PhD, Joshua Epstein, DSc, Malcolm K. Brenner, MD, PhD, Adrian P. Gee, PhD, Michele H. Cottler-Fox, MD, Bart Barlogie, MD, PhD, Cliona M. Rooney, PhD, Frits van Rhee, MD, PhD

Blood (2012) 120 (21): 1912.

https://doi.org/10.1182/blood.V120.21.1912.1912

Published: 2012

Journal Articles

Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients

Blood (2012) 120 (21): 579.

https://doi.org/10.1182/blood.V120.21.579.579

Published: 2012

Journal Articles

TRAIL expression by activated human CD4 + Vα24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells

Mie Nieda, Andrew Nicol, Yashuhiko Koezuka, Akiko Kikuchi, Natalia Lapteva, Yuji Tanaka, Katsushi Tokunaga, Kenji Suzuki, Nobuhiko Kayagaki, Hideo Yagita, Hisamaru Hirai, Takeo Juji

Blood (2001) 97 (7): 2067–2074.

https://doi.org/10.1182/blood.V97.7.2067

Published: 2001

NARROW

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

Rapidly-Generated EBV-Specific T Cells (EBVST-cells) to Treat Type 2 Latency Lymphoma

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Optimizing the Manufacture of CAR-T Cells for Clinical Applications

Optimal Xenogeneic Adoptive Transfer of Human NK Cells: Fresh NK Cells and IL-15 Administration Are Superior to Frozen NK Cells and IL-2

Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order

Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients

TRAIL expression by activated human CD4 + Vα24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only